As President Donald Trump hits 100 days in his second term, the administration is touting the billions of investments companies such as Apple and Merck are making in the United States ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report), Vertex Pharmaceuticals (VRTX – Research Report ...

Legislation designed to constrain prescription drug costs and protect rural pharmacies by regulating third-party health care ...

Merck announced Monday it will acquire U.S. biotech company SpringWorks Therapeutics for $47 per share in cash, valuing the ...

Quantum computing has long been announced as “just around the corner,” but several companies are now determined to make this ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Akshay Vaishnaw, M.D., Ph.D., has been appointed to the newly created role of President of R&D. He was formerly the President ...

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...

Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around ...